CD79A Human Recombinant
CD79B Human Recombinant
CD79B Human Recombinant, Sf9
CD79, also known as Cluster of Differentiation 79, is a transmembrane protein that forms a complex with the B-cell receptor (BCR) and generates a signal following the recognition of an antigen by the BCR. CD79 is composed of two distinct chains called CD79A and CD79B (also known as Igα and Igβ), which form a heterodimer on the surface of a B cell stabilized by disulfide bonding . Both CD79A and CD79B are members of the immunoglobulin superfamily .
Key Biological Properties: CD79A and CD79B contain an immunoreceptor tyrosine-based activation motif (ITAM) in their intracellular tails, which they use to propagate a signal in a B cell .
Expression Patterns and Tissue Distribution: CD79 is expressed by B-cell and plasma cell precursors. It is highly expressed in immune tissues such as the spleen, head kidney, and kidney, with relatively low levels detected in the heart, gill, and liver .
Primary Biological Functions: CD79 serves as a pan-B cell marker for the detection of B-cell neoplasms. It plays a crucial role in B cell development and antibody production .
Role in Immune Responses and Pathogen Recognition: CD79 is involved in the activation of B cells upon antigen recognition, leading to the initiation of immune responses .
Mechanisms with Other Molecules and Cells: CD79 forms a complex with the BCR and generates a signal following antigen recognition. Upon antigen-induced BCR aggregation, CD79 is phosphorylated and initiates a cascade of downstream signaling events .
Binding Partners and Downstream Signaling Cascades: CD79 interacts with various signaling molecules, including SRC-family kinase LYN, SYK, phospholipase C (PLC)-γ, BLNK, and BTK, to propagate BCR signaling .
Biomedical Research: CD79 is used as a marker for B-cell neoplasms and is a target for therapeutic strategies in autoimmune diseases and B-cell malignancies .
Diagnostic Tools: CD79 monoclonal antibodies are used in diagnostic tools to detect B-cell neoplasms .
Therapeutic Strategies: CD79 is a target for antibody-drug conjugates and chimeric antigen receptor T cell therapies for autoimmunity and B cell neoplasia .